or Try an Advanced Search...

    Technical Analysis for INZY - Inozyme Pharma, Inc.

    Grade Last Price % Change Price Change
    F 4.82 2.77% 0.13
    INZY closed up 2.77 percent on Friday, May 31, 2024, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical INZY trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Up 3 Days in a Row Strength 0.00%
    Crossed Above 20 DMA Bullish 2.77%
    Crossed Above 200 DMA Bullish 2.77%
    Bollinger Band Squeeze Range Contraction 2.77%
    BB Squeeze + Upper Band Touch Range Contraction 2.77%
    Gapped Up Strength 2.77%
    Upper Bollinger Band Touch Strength 2.77%
    Older End-of-Day Signals for INZY ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High 2 days ago
    Rose Above Upper Bollinger Band 2 days ago
    Possible NR7 2 days ago
    Possible Inside Day 2 days ago
    Up 3% 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    INZY Chart by TradingView
    Basic chart:

    Profile

    Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna

    Is INZY a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 30 Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
    May 23 Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
    May 8 Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
    May 8 Inozyme Pharma GAAP EPS of -$0.38 beats by $0.02
    May 7 Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
    May 3 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Apr 9 Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Apr 8 Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
    Apr 2 Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
    Mar 28 Top 5 Health Care Stocks That May Plunge In March
    See more INZY news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.795
    52 Week Low 2.689
    Average Volume 643,738
    200-Day Moving Average 4.63
    50-Day Moving Average 5.14
    20-Day Moving Average 4.64
    10-Day Moving Average 4.63
    Average True Range 0.23
    RSI (14) 53.05
    ADX 21.89
    +DI 20.31
    -DI 21.12
    Chandelier Exit (Long, 3 ATRs) 4.20
    Chandelier Exit (Short, 3 ATRs) 5.03
    Upper Bollinger Bands 4.86
    Lower Bollinger Band 4.42
    Percent B (%b) 0.9
    BandWidth 9.45
    MACD Line -0.09
    MACD Signal Line -0.13
    MACD Histogram 0.0464
    Fundamentals Value
    Market Cap 297.69 Million
    Num Shares 61.8 Million
    EPS -1.44
    Price-to-Earnings (P/E) Ratio -3.35
    Price-to-Sales 0.00
    Price-to-Book 2.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.03
    Resistance 3 (R3) 5.02 4.94 5.00
    Resistance 2 (R2) 4.94 4.89 4.95 4.98
    Resistance 1 (R1) 4.88 4.85 4.91 4.89 4.97
    Pivot Point 4.80 4.80 4.82 4.81 4.80
    Support 1 (S1) 4.74 4.75 4.77 4.75 4.67
    Support 2 (S2) 4.66 4.71 4.67 4.66
    Support 3 (S3) 4.60 4.66 4.65
    Support 4 (S4) 4.61